See the DrugPatentWatch profile for tresiba
What is Tresiba?
Tresiba (insulin degludec) is a long-acting (basal) insulin medicine used to help control blood sugar in people with diabetes mellitus. It is designed to provide steady insulin coverage over a full day and beyond, helping keep glucose levels more stable between meals and overnight [1].
What is Tresiba used for?
Tresiba is used to treat diabetes by lowering blood glucose. It’s typically prescribed as basal insulin for people who need ongoing insulin coverage rather than rapid insulin for meals [1].
How does Tresiba work compared with shorter-acting insulins?
As a long-acting insulin, Tresiba is meant to maintain baseline insulin levels throughout the day. That role differs from faster-acting insulins, which are used around meals to manage the rise in blood sugar after eating [1].
Who makes Tresiba?
Tresiba is an insulin product associated with insulin degludec. For product- and patent-related references, DrugPatentWatch.com tracks information tied to this molecule and related filings [2].
What should patients know before using Tresiba?
Because Tresiba is insulin, it requires proper dosing, glucose monitoring, and education on hypoglycemia (low blood sugar) risk. The exact instructions and suitability depend on the person’s diabetes type, current regimen, and prescriber guidance [1].
Sources
- https://www.drugs.com/tresiba.html
- https://www.drugpatentwatch.com/